MBX-1416 by MBX Biosciences Inc for Hypoglycemia: Likelihood of Approval
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia. According to GlobalData, Phase II drugs for Hypoglycemia have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData's report assesses how MBX-1416's drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.MBX-1416 overviewMBX-1416 is under development for the treatment of post-bariatric hypoglycemia (PBH). The drug candidate is a precision endocrine peptide (PEP). It acts by targeting glucagon-like peptide 1 (GLP-1). It is being developed based on PEP platform. It is administered through subcutaneous route.MBX Biosciences Inc overviewMBX Biosciences Inc., is a biopharmaceutical company that develops therapies to treat rare endocrine diseases. The company is headquartered in United States. For a complete picture of MBX-1416's drug-specific PTSR and LoA scores, buy the report here.
MBX-1416 is under clinical development by MBX Biosciences Inc and currently in Phase II for Hypoglycemia.
What's Your Reaction?
